

Management of asthma in school-age children on therapy

| | | |
|--|---|---|
| Submission date 08/11/2007 | Recruitment status No longer recruiting | <input checked="" type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol |
| Registration date 19/11/2007 | Overall study status Completed | <input type="checkbox"/> Statistical analysis plan <input checked="" type="checkbox"/> Results |
| Last Edited 13/02/2020 | Condition category Respiratory | <input type="checkbox"/> Individual participant data |

Plain English summary of protocol

Background and study aims

Asthma is a common long-term condition that can cause coughing, wheezing, chest tightness and breathlessness. It affects 1 in 8 children in the UK. Up to half of these are treated with preventative medicine in the form of low-dose steroids using an inhaler. The National Asthma Treatment Guidelines recommend when this treatment is not working other treatments should be started. Studies to support this have taken place in adults but not with children.

Who can participate?

Children with asthma aged 6 - 14

What does the study involve?

If patients are instructed how to use inhalers and are given information about asthma, they can control their disease much better. The first part of this study, lasting 4 weeks, makes sure that the children and their families understand how to use their inhaler. All participating children are given the same steroid inhaler to use and after 4 weeks those still with symptoms enter the study proper which lasts for 48 weeks. During this part of the study the children are randomly allocated to be given one of three treatments: a steroid inhaler and a dummy tablet; an inhaler containing a steroid and a long-acting reliever and a dummy tablet; or a steroid inhaler and an active tablet. What matters to children is how they feel, are they able to run around and play with friends, and are they well enough to go to school. We assess which of the above treatments best allow these to happen by asking the parents and children to fill in questionnaires on four occasions during the study. We also assess which treatment best prevents the need for short courses of steroid tablets during the study. These are commonly given when asthma symptoms worsen.

What are the possible benefits and risks of participating?

Not provided at time of registration

Where is the study run from?

North Staffordshire Medical Institute (UK)

When is the study starting and how long is it expected to run for?
January 2009 to September 2011

Who is funding the study?
Health Technology Assessment Programme (UK)

Who is the main contact?
Prof. Warren Lenney

Contact information

Type(s)
Scientific

Contact name
Prof Warren Lenney

Contact details
Research & Development Department
North Staffordshire Medical Institute
Hartshill Road
Hartshill
Stoke-on-Trent
United Kingdom
ST4 7QB

Additional identifiers

ClinicalTrials.gov (NCT)
NCT01526161

Protocol serial number
HTA 05/503/04

Study information

Scientific Title
Management of Asthma in School-age Children On Therapy

Acronym
MASCOT

Study objectives
Children whose asthma is uncontrolled on low dose Inhaled Corticosteroids (ICS) will have their control improved by prescribing 'add-on' therapies (long-acting beta-2 agonists and/or leukotriene receptor antagonists) in addition to low dose ICS treatment.

More details can be found at: <http://www.nets.nihr.ac.uk/projects/hta/0550304>
Protocol can be found at: http://www.nets.nihr.ac.uk/__data/assets/pdf_file/0013/51223/PRO-05-503-04.pdf

Ethics approval required

Old ethics approval format

Ethics approval(s)

North West Research Ethics Committee, 03/04/2008, ref: 08/H1010/8

Primary study design

Interventional

Study design

Prospective controlled double-blind multicentre randomised clinical trial

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Asthma (paediatric population)

Interventions

1. Inhaled fluticasone propionate 100 µg twice daily plus placebo tablet once daily
2. Inhaled fluticasone propionate 100 µg and salmeterol 50 µg twice daily (combination inhaler) plus placebo tablet once daily
3. Inhaled fluticasone propionate 100 µg twice daily plus montelukast 5 mg tablet once daily

There is a four week run-in period, followed by a 48 week intervention and follow up period (for those patients eligible at randomisation). Patients in the randomised phase will receive study treatment for the full 48 weeks.

Intervention Type

Drug

Phase

Not Applicable

Drug/device/biological/vaccine name(s)

Fluticasone propionate, salmeterol, montelukast

Primary outcome(s)

The main research objective is to determine, in 6 - 14 year old children with asthma, uncontrolled on low-dose ICS, whether their control can be improved by adding in a long-acting beta-2 agonist (salmeterol) or a leukotriene receptor antagonist (montelukast) as measured by a reduced number of exacerbations requiring treatment with oral corticosteroids over the 48 week study period.

Key secondary outcome(s)

1. Quality of Life measured by the Juniper QoL questionnaire, collected at baseline, randomisation, then +8 weeks, +24 weeks, +36 weeks and +48 weeks
2. Time from randomisation to first exacerbation requiring treatment with a short course of oral corticosteroids, collected at baseline, randomisation, then +8 weeks, +24 weeks, +36 weeks and +48 weeks

3. School attendance, collected at baseline, randomisation, then +8 weeks, +24 weeks, +36 weeks and +48 weeks
4. Hospital admissions, collected at baseline, randomisation, then +8 weeks, +24 weeks, +36 weeks and +48 weeks
5. Amount of rescue beta-2 agonist therapy prescribed, collected at baseline, randomisation, then +8 weeks, +24 weeks, +36 weeks and +48 weeks
6. Time from randomisation to treatment withdrawal (due to lack of efficacy or side effects), collected at baseline, randomisation, then +8 weeks, +24 weeks, +36 weeks and +48 weeks
7. Lung function (as assessed by spirometry), conducted at baseline/randomisation (T0) and randomisation + 48 weeks (T48)

Completion date

30/09/2011

Eligibility

Key inclusion criteria

1. Children with physician diagnosed asthma aged 6 years - 14 years 11 months
2. Those requiring frequent short-acting beta-2 agonist relief therapy greater than or equal to 7 puffs per week
3. Those with symptoms of asthma (i.e. wheeze, shortness of breath but not cough) resulting in:
 - 3.1. Difficulty sleeping in the last week because of asthma symptoms and/or
 - 3.2. Asthma has interfered with usual activities in the last week and/or
 - 3.3. Those who have had exacerbations, defined as a short course of oral corticosteroids, an unscheduled General Practitioner (GP) or Accident and Emergency (A&E) Department visit or a hospital admission within the previous 6 months
4. Fully informed consent written (proxy) consent and assent, where appropriate

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Child

Lower age limit

6 Years

Upper age limit

14 Years

Sex

All

Key exclusion criteria

1. Children receiving long acting beta-2-agonists, leukotriene receptor antagonists, regular theophylline therapy or high dose ICS
2. Children with other respiratory diseases, cystic fibrosis, cardiac disease or immunological disorders

Date of first enrolment

01/01/2009

Date of final enrolment

30/09/2011

Locations

Countries of recruitment

United Kingdom

England

Study participating centre

North Staffordshire Medical Institute

Stoke-on-Trent

United Kingdom

ST4 7QB

Sponsor information

Organisation

University Hospital of North Staffordshire NHS Trust (UK)

Organisation

Keele University (UK)

Organisation

University Hospital of North Staffordshire NHS Trust

Funder(s)

Funder type

Government

Funder Name

Health Technology Assessment Programme

Alternative Name(s)

NIHR Health Technology Assessment Programme, Health Technology Assessment (HTA), HTA

Funding Body Type

Government organisation

Funding Body Subtype

National government

Location

United Kingdom

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Study outputs

| Output type | Details | Date created | Date added | Peer reviewed? | Patient-facing? |
|---------------------------------|---------|--------------|------------|----------------|-----------------|
| Results article | results | 01/02/2013 | | Yes | No |